Ketamin-tilføjelse til terapi til etableret status epilepticus behandlingsforsøg (KESETT) (KESETT)
The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
KESETT is a multicenter, randomized, blinded study to determine whether adding 1 mg/kg or 3 mg/kg dose of KET to 60 mg/kg LEV can terminate status epilepticus (SE) in a larger fraction of subjects with benzodiazepine-refractory SE than those treated with LEV (60 mg/kg) alone.
The primary outcome is termination of SE from 15 minutes after starting the study drug infusion, sustained until 60 minutes from enrollment without using additional anti-seizure medication. Termination of SE is determined by (1) improving consciousness and absence of clinically apparent seizures at 60 minutes or (2) absence of any electrographic SE after 15 minutes in those with EEG monitoring and no improvement in consciousness.
Secondary objectives include determining the relative safety of the treatment arms on defined safety outcomes and all adverse events, analysis of secondary/exploratory efficacy outcomes, and evaluation of both effectiveness and safety in the pediatric subpopulation.
The trial will initially allocate subjects equally (1:1:1) for the first 350 participants (burn-in period) before transitioning to response-adaptive randomization. Interim analyses will be conducted for efficacy and futility beginning when 350 subjects have been randomized, and will occur every 100 subjects thereafter. A maximum of 770 participants will be enrolled.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Megan Wardius
- Telefonnummer: 434-243-6768
- E-mail: mew5j@virginia.edu
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Ikke rekrutterer endnu
- UAB Hospital
-
Kontakt:
- Lauren Walter, MD, MSPH
- Telefonnummer: 205-996-4791
- E-mail: lwalter@uabmc.edu
-
Ledende efterforsker:
- Lauren Walter, MD, MSPH
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85724
- Rekruttering
- Banner University Medical Center - Tucson Campus
-
Kontakt:
- Aaron Leetch, MD
- Telefonnummer: 520-621-8752
- E-mail: aleetch@arizona.edu
-
Ledende efterforsker:
- Aaron Leetch, MD
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- Ikke rekrutterer endnu
- UC San Diego Health La Jolla
-
Kontakt:
- Vanessa Tamas, MD
- Telefonnummer: 858-966-8033
- E-mail: vtamas@rchsd.org
-
Ledende efterforsker:
- Vanessa Tamas, MD
-
Los Angeles, California, Forenede Stater, 90027
- Ikke rekrutterer endnu
- Children's Hospital Los Angeles
-
Kontakt:
- Ara Festekjian, MD
- Telefonnummer: 323-804-8142
- E-mail: afestekjian@chla.usc.edu
-
Ledende efterforsker:
- Ara Festekjian, MD
-
Los Angeles, California, Forenede Stater, 90024
- Ikke rekrutterer endnu
- Ronald Reagan UCLA Medical Center
-
Kontakt:
- Richelle Cooper, MD
- Telefonnummer: 424-440-0486
- E-mail: rcooper@mednet.ucla.edu
-
Ledende efterforsker:
- Richelle Cooper, MD
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Stanford University Medical Center
-
Kontakt:
- Alexandra June Gordon, MD
- Telefonnummer: 650-248-7701
- E-mail: ajgordon@stanford.edu
-
Ledende efterforsker:
- Alexandra June Gordon, MD
-
Sacramento, California, Forenede Stater, 95817
- Rekruttering
- UC Davis Medical Center
-
Ledende efterforsker:
- Daniel Nishijima, MD
-
Kontakt:
- Daniel Nishijima, MD
- Telefonnummer: 916-734-5010
- E-mail: dnishijima@ucdavis.edu
-
San Diego, California, Forenede Stater, 92123
- Ikke rekrutterer endnu
- Rady Children's Hospital
-
Kontakt:
- Vanessa Tamas, MD
- Telefonnummer: 858-966-8033
- E-mail: vtamas@rchsd.org
-
Ledende efterforsker:
- Vanessa Tamas, MD
-
San Diego, California, Forenede Stater, 92103
- Ikke rekrutterer endnu
- UC San Diego Health Hillcrest Hospital
-
Kontakt:
- Vanessa Tamas, MD
- Telefonnummer: 858-966-8033
- E-mail: vtamas@rchsd.org
-
Ledende efterforsker:
- Vanessa Tamas, MD
-
San Francisco, California, Forenede Stater, 94143
- Rekruttering
- UCSF Medical Center
-
Kontakt:
- Debbie Madhok, MD
- Telefonnummer: 415-601-6399
- E-mail: Debbie.madhok@ucsf.edu
-
Ledende efterforsker:
- Debbie Madhok, MD
-
San Francisco, California, Forenede Stater, 94143
- Rekruttering
- San Francisco General Hospital
-
Kontakt:
- Debbie Madhok, MD
- Telefonnummer: 415-601-6399
- E-mail: Debbie.madhok@ucsf.edu
-
Ledende efterforsker:
- Debbie Madhok, MD
-
Torrance, California, Forenede Stater, 90502
- Ikke rekrutterer endnu
- Harbor-UCLA Medical Center
-
Kontakt:
- Juliana Tolles, MD
- Telefonnummer: 434-243-6768
- E-mail: jtolles@emedharbor.edu
-
Ledende efterforsker:
- Juliana Tolles, MD
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06519
- Rekruttering
- Yale New Haven Hospital
-
Kontakt:
- Charles Wira, MD
- Telefonnummer: 203-785-5781
- E-mail: charles.wira@yale.edu
-
Ledende efterforsker:
- Charles Wira, MD
-
-
Delaware
-
Newark, Delaware, Forenede Stater, 19718
- Rekruttering
- Christiana Hospital
-
Ledende efterforsker:
- Jason Nomura, MD
-
Kontakt:
- Jason Nomura, MD
- Telefonnummer: 302-733-4113
- E-mail: jnomura@christianacare.org
-
Wilmington, Delaware, Forenede Stater, 19803
- Rekruttering
- Nemours Children's Hospital
-
Kontakt:
- Amy Thompson, MD
- Telefonnummer: 302-490-4146
- E-mail: amy.thompson@nemours.org
-
Ledende efterforsker:
- Amy Thompson, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Rekruttering
- Children's National Medical Center
-
Ledende efterforsker:
- James Chamberlain, MD
-
Kontakt:
- James Chamberlain, MD
- Telefonnummer: 202-476-8877
- E-mail: jchamber@childrensnational.org
-
-
Florida
-
Orlando, Florida, Forenede Stater, 32806
- Rekruttering
- Orlando Regional Medical Center
-
Kontakt:
- Dipali Nemade, MD
- Telefonnummer: 321-841-1324
- E-mail: Dipali.Nemade@orlandohealth.com
-
Ledende efterforsker:
- Dipali Nemade, MD
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Rekruttering
- Arthur M. Blank Hospital
-
Ledende efterforsker:
- Claudia Morris, MD
-
Kontakt:
- Claudia Morris, MD
- Telefonnummer: 404-785-7070
- E-mail: claudia.r.morris@emory.edu
-
Atlanta, Georgia, Forenede Stater, 30303
- Aktiv, ikke rekrutterende
- Grady Memorial Hospital
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rekruttering
- Rush University Medical Center
-
Kontakt:
- Michael Gottlieb, MD, MBA
- Telefonnummer: 631-922-1705
- E-mail: Michael_A_Gottlieb@rush.edu
-
Ledende efterforsker:
- Michael Gottlieb, MD, MBA
-
Chicago, Illinois, Forenede Stater, 60611
- Ikke rekrutterer endnu
- Northwestern Memorial Hospital
-
Kontakt:
- Peter Pruitt, MD
- Telefonnummer: 312-694-7000
- E-mail: peter.pruitt@nm.org
-
Ledende efterforsker:
- Peter Pruitt, MD
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- Comer Children's Hospital
-
Kontakt:
- David Beiser, MD
- Telefonnummer: 773-834-4135
- E-mail: dbeiser@medicine.bsd.uchicago.edu
-
Ledende efterforsker:
- David Beiser, MD
-
Chicago, Illinois, Forenede Stater, 60612
- Ikke rekrutterer endnu
- University of Illinois Hospital
-
Kontakt:
- Pavitra Kotini-Shah, MD
- Telefonnummer: 817-703-1723
- E-mail: pkotini@uic.edu
-
Ledende efterforsker:
- Pavitra Kotini-Shah, MD
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago Medical Center
-
Kontakt:
- David Beiser, MD
- Telefonnummer: 773-834-4135
- E-mail: dbeiser@medicine.bsd.uchicago.edu
-
Ledende efterforsker:
- David Beiser, MD
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Riley Hospital for Children
-
Kontakt:
- Benjamin Nti, MD
- Telefonnummer: 317-416-7997
- E-mail: bnti@iu.edu
-
Ledende efterforsker:
- Benjamin Nti, MD
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- IU Health Methodist Hospital
-
Kontakt:
- Daniel Udrea, MD
- Telefonnummer: 317-274-0829
- E-mail: dudrea@iu.edu
-
Ledende efterforsker:
- Daniel Udrea, MD
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa Medical Center
-
Kontakt:
- Brett Faine, MD
- Telefonnummer: 319-384-5228
- E-mail: brett-faine@uiowa.edu
-
Ledende efterforsker:
- Brett Faine, MD
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70112
- Ikke rekrutterer endnu
- University Medical Center New Orleans
-
Ledende efterforsker:
- Stephen Lim, MD
-
Kontakt:
- Stephen Lim, MD
- Telefonnummer: 504-702-2440
- E-mail: slim@lsuhsc.edu
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- Rekruttering
- University of Maryland Medical Center
-
Kontakt:
- Jennifer Hopp, MD
- Telefonnummer: 410-328-7635
- E-mail: jhopp@som.umaryland.edu
-
Ledende efterforsker:
- Jennifer Hopp, MD
-
Baltimore, Maryland, Forenede Stater, 21287
- Rekruttering
- Johns Hopkins Hospital
-
Kontakt:
- Kathryn Rosenblatt, MD
- Telefonnummer: 410-955-6488
- E-mail: krosenb3@jhmi.edu
-
Ledende efterforsker:
- Kathryn Rosenblatt, MD
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Ikke rekrutterer endnu
- Massachusetts General Hospital
-
Kontakt:
- Michael Filbin, MD
- Telefonnummer: 617-724-4758
- E-mail: mfilbin@mgh.harvard.edu
-
Ledende efterforsker:
- Michael Filbin, MD
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan University Hospital
-
Kontakt:
- Mariama Runcie, MD
- Telefonnummer: 734-232-2145
- E-mail: runciema@med.umich.edu
-
Ledende efterforsker:
- Mariama Runcie, MD
-
Detroit, Michigan, Forenede Stater, 48201
- Rekruttering
- Detroit Receiving Hospital
-
Kontakt:
- Wazim Mohamed, MD
- Telefonnummer: 313-577-8824
- E-mail: wmohamed@med.wayne.edu
-
Ledende efterforsker:
- Wazim Mohamed, MD
-
Detroit, Michigan, Forenede Stater, 48202
- Ikke rekrutterer endnu
- Henry Ford Hospital
-
Ledende efterforsker:
- Joseph Miller, MD
-
Kontakt:
- Joseph Miller, MD
- Telefonnummer: 313-404-9110
- E-mail: jmiller6@hfhs.org
-
Detroit, Michigan, Forenede Stater, 48201
- Rekruttering
- Sinai-Grace Hospital
-
Kontakt:
- Arun Sherma, MD
- Telefonnummer: 313-745-4238
- E-mail: arun@sherma.org
-
Ledende efterforsker:
- Arun Sherma, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- Rekruttering
- University of Minnesota Medical Center
-
Kontakt:
- James Miner, MD
- Telefonnummer: 612-624-7426
- E-mail: miner015@umn.edu
-
Ledende efterforsker:
- James Miner, MD
-
Minneapolis, Minnesota, Forenede Stater, 55415
- Ikke rekrutterer endnu
- Hennepin County Medical Center
-
Ledende efterforsker:
- Brian Driver, MD
-
Kontakt:
- Brian Driver, MD
- Telefonnummer: 612-873-7448
- E-mail: brian.driver@hcmed.org
-
Minneapolis, Minnesota, Forenede Stater, 55414
- Rekruttering
- University of Minnesota Masonic Children's Hospital
-
Kontakt:
- James Miner, MD
- Telefonnummer: 612-624-7426
- E-mail: miner015@umn.edu
-
Ledende efterforsker:
- James Miner, MD
-
-
New Jersey
-
Camden, New Jersey, Forenede Stater, 08103
- Ikke rekrutterer endnu
- Cooper University Hospital
-
Ledende efterforsker:
- Christopher Jones, MD
-
Kontakt:
- Christopher Jones, MD
- Telefonnummer: 856-342-2637
- E-mail: jones-christopher@cooperhealth.edu
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Ikke rekrutterer endnu
- University of New Mexico Hospital
-
Kontakt:
- Masoom Desai, MD
- Telefonnummer: 505-272-0356
- E-mail: MDesai@salud.unm.edu
-
Ledende efterforsker:
- Masoom Desai, MD
-
-
New York
-
Syracuse, New York, Forenede Stater, 13210
- Ikke rekrutterer endnu
- SUNY Upstate Medical University
-
Kontakt:
- Lindsay Nausin, DO
- Telefonnummer: 315-464-4363
- E-mail: nausinl@upstate.edu
-
Ledende efterforsker:
- Lindsay Nausin, DO
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Rekruttering
- Duke University Hospital
-
Kontakt:
- Alexander Limkakeng, MD
- Telefonnummer: 919-681-0908
- E-mail: alexander.limkakeng@duke.edu
-
Ledende efterforsker:
- Alexander Limkakeng, MD
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267
- Rekruttering
- University of Cincinnati Medical Center
-
Kontakt:
- Jason McMullan, MD
- Telefonnummer: 513-675-3072
- E-mail: jason.mcmullan@uc.edu
-
Ledende efterforsker:
- Jason McMullan, MD
-
Columbus, Ohio, Forenede Stater, 43205
- Rekruttering
- Nationwide Children's Hospital
-
Kontakt:
- Aarti Gaglani Aarti Gaglani, MD
- Telefonnummer: 6147226910
- E-mail: kesett@nationwidechildrens.org
-
Ledende efterforsker:
- Aarti Gaglani, MD
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- OSU Wexner Medical Center
-
Kontakt:
- Kirstin Acus, MD
- Telefonnummer: 614-293-6185
- E-mail: kirstin.acus@osumc.edu
-
Ledende efterforsker:
- Kirstin Acus, MD
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Rekruttering
- Oregon Health & Science University Hospital
-
Kontakt:
- Bory Kea, MD
- Telefonnummer: 503-494-8083
- E-mail: kea@ohsu.edu
-
Ledende efterforsker:
- Bory Kea, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Ikke rekrutterer endnu
- Hospital of the University of Pennsylvania
-
Kontakt:
- John Greenwood, MD
- Telefonnummer: 267-252-8741
- E-mail: john.greenwood@pennmedicine.upenn.edu
-
Ledende efterforsker:
- John Greenwood, MD
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Ikke rekrutterer endnu
- Penn Presbyterian Medical Center
-
Kontakt:
- John Greenwood, MD
- Telefonnummer: 267-252-8741
- E-mail: john.greenwood@pennmedicine.upenn.edu
-
Ledende efterforsker:
- John Greenwood, MD
-
Philadelphia, Pennsylvania, Forenede Stater, 19141
- Rekruttering
- Jefferson Einstein Philadelphia Hospital
-
Kontakt:
- Joseph Herres, DO
- Telefonnummer: 215-457-5865
- E-mail: Joseph.herres@jefferson.edu
-
Ledende efterforsker:
- Joseph Herres, DO
-
Philadelphia, Pennsylvania, Forenede Stater, 19111
- Rekruttering
- Temple University Hospital Jeanes Campus
-
Kontakt:
- Derek Isenberg, MD
- Telefonnummer: 215-707-0222
- E-mail: derek.isenberg@tuhs.temple.edu
-
Ledende efterforsker:
- Derek Isenberg, MD
-
Philadelphia, Pennsylvania, Forenede Stater, 19140
- Rekruttering
- Temple University Hospital Main Campus
-
Kontakt:
- Derek Isenberg, MD
- Telefonnummer: 215-707-0222
- E-mail: derek.isenberg@tuhs.temple.edu
-
Ledende efterforsker:
- Derek Isenberg, MD
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- Rekruttering
- UPMC Presbyterian Hospital
-
Kontakt:
- Adam Frisch, MD
- Telefonnummer: 412-647-9047
- E-mail: frischan@upmc.edu
-
Ledende efterforsker:
- Adam Frisch, MD
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- UPMC Children's Hospital of Pittsburgh
-
Kontakt:
- Robert Hickey, MD
- Telefonnummer: 412-692-6567
- E-mail: robert.hickey@chp.edu
-
Ledende efterforsker:
- Robert Hickey, MD
-
West Reading, Pennsylvania, Forenede Stater, 19611
- Rekruttering
- Reading Hospital
-
Kontakt:
- Adam Sigal, MD
- Telefonnummer: 484-628-7016
- E-mail: adam.sigal@towerhealth.org
-
Ledende efterforsker:
- Adam Sigal, MD
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75235
- Ikke rekrutterer endnu
- Children's Medical Center Dallas
-
Kontakt:
- Pamela Okada, MD
- Telefonnummer: 67102 214-456-7000
- E-mail: pamela.okada@utsouthwestern.edu
-
Ledende efterforsker:
- Pamela Okada, MD
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Memorial Hermann Texas Medical Center
-
Kontakt:
- Kayleigh Fischer, MD
- Telefonnummer: 713-500-7803
- E-mail: Kayleigh.A.Fischer@uth.tmc.edu
-
Ledende efterforsker:
- Kayleigh Fischer, MD
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84108
- Rekruttering
- Primary Children's Hospital
-
Kontakt:
- Maija Holsti, MD, MPH
- Telefonnummer: 801-656-8833
- E-mail: Maija.Holsti@hsc.utah.edu
-
Ledende efterforsker:
- Maija Holsti, MD, MPH
-
Salt Lake City, Utah, Forenede Stater, 84112
- Rekruttering
- University of Utah Healthcare
-
Kontakt:
- Scott Youngquist, MD
- Telefonnummer: 801-349-0241
- E-mail: scott.youngquist@utah.edu
-
Ledende efterforsker:
- Scott Youngquist, MD
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Rekruttering
- University of Virginia Medical Center
-
Ledende efterforsker:
- Thomas Hartka, MD
-
Kontakt:
- Thomas Hartka, MD
- Telefonnummer: 434-924-2897
- E-mail: trh6u@uvahealth.org
-
Richmond, Virginia, Forenede Stater, 23298
- Ikke rekrutterer endnu
- VCU Medical Center
-
Kontakt:
- Lisa Merck, MD, MPH, MHA
- Telefonnummer: 862-383-1688
- E-mail: Lisa.Merck@vcuhealth.org
-
Ledende efterforsker:
- Lisa Merck, MD, MPH, MHA
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- Rekruttering
- Harborview Medical Center
-
Kontakt:
- Vasisht Srinivasan, MD
- Telefonnummer: 585-730-3843
- E-mail: vasishts@uw.edu
-
Ledende efterforsker:
- Vasisht Srinivasan, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Children's Hospital of Wisconsin
-
Kontakt:
- Keli Coleman, MD
- Telefonnummer: 414-266-2767
- E-mail: kcoleman@mcw.edu
-
Ledende efterforsker:
- Keli Coleman, MD
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Froedtert Hospital
-
Kontakt:
- Jamie Jasti, MD
- Telefonnummer: 414-805-6493
- E-mail: jjasti@mcw.edu
-
Ledende efterforsker:
- Jamie Jasti, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- The patient was witnessed to have a convulsive seizure for greater than 5-minute duration
- The patient received an adequate dose of benzodiazepines. The doses may be divided.
- The last dose of a benzodiazepine was administered 5-30 minutes before study drug administration.
- Continued or recurring seizures in the Emergency Department.
- Age 1 years or older
- Known or estimated weight ≥10 Kg
Exclusion Criteria:
- Known pregnancy
- Prisoner
- Opt-out identification or otherwise known to be previously enrolled in KESETT
- Treatment with a second line anticonvulsant (FOS, PHT, VPA, LEV, phenobarbital, or other agents defined in the MoP) for this episode of SE
- Treatment with sedatives with anticonvulsant properties other than benzodiazepines for this episode of SE(propofol, etomidate, ketamine or other agents defined in the MoP)
- Endotracheal intubation prior to enrollment
- Acute traumatic brain injury clearly precedes seizures
- Scalp injury or burn preventing EEG placement
- Known allergy or other known contraindication to KET or LEV
- Hypoglycemia < 50 mg/dL
- Hyperglycemia > 400 mg/dL
- Cardiac arrest / post-anoxic seizures
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Levetiracetam
Levetiracetam (LEV) (60 mg/Kg) |
The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study. All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded. |
|
Eksperimentel: Levetiracetam + low dose Ketamine
LEV 60 mg/mL + 1 mg/mL KET |
The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study. All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded. |
|
Eksperimentel: Levetiracetam + high dose Ketamine
LEV 60 mg/mL + 3 mg/mL KET increasing up to a weight of 75 kg |
The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study. All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Termination of SE
Tidsramme: From 15 minutes after starting the study drug infusion, sustained for 60 minutes without using additional anti-seizure medication.
|
Termination of SE from 15 minutes after starting the study drug infusion, sustained for 60 minutes without using additional anti-seizure medication. Termination of SE is determined by (1) improving consciousness and absence of clinically apparent seizures at 60 minutes or (2) absence of any electrographic status epilepticus (ESE) after 15 minutes in those with EEG monitoring and no improvement in consciousness. |
From 15 minutes after starting the study drug infusion, sustained for 60 minutes without using additional anti-seizure medication.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Desirability of response (DOOR) outcome
Tidsramme: 60 minutes after starting the study drug infusion
|
One secondary outcome will be a desirability of response (DOOR) outcome which is a composite efficacy measure evaluated on a graded scale from 1 to 5 at 60 minutes, as follows:
The Central Adjudication Core will determine the DOOR grade (1-5) based on clinical outcome data provided by the site and EEG data provided by the Central EEG Core. |
60 minutes after starting the study drug infusion
|
|
Endotracheal intubation
Tidsramme: Within 60 minutes after start of the study drug infusion
|
Endotracheal intubation within 60 minutes of randomization (start of study drug infusion) and duration |
Within 60 minutes after start of the study drug infusion
|
|
ICU duration
Tidsramme: Up to 30 days after enrollment
|
ICU duration during the study period for those that are admitted to the ICU as abstracted from the hospital admission record |
Up to 30 days after enrollment
|
|
Hospital length-of-stay (LOS)
Tidsramme: Up to 30 days after enrollment
|
Hospital length-of-stay (LOS) from the ED as abstracted from the hospital admission record |
Up to 30 days after enrollment
|
|
Late recurrent seizure
Tidsramme: Between 60 minutes and 4 hours after the start of the study drug infusion
|
Number of participants with late recurrent seizure between 60 minutes and 4 hours after the start of the study drug infusion |
Between 60 minutes and 4 hours after the start of the study drug infusion
|
|
Time to termination of seizures
Tidsramme: From the start of infusion of study drug to the cessation of electrographic seizure assessed up to 60 minutes from study drug initiation
|
The interval from the start of infusion of study drug to the cessation of electrographic seizure in those who meet the primary outcome |
From the start of infusion of study drug to the cessation of electrographic seizure assessed up to 60 minutes from study drug initiation
|
|
Late seizures after requiring an anesthetic
Tidsramme: Between 60 minutes and 24 hours after start of study drug infusion
|
Number of participants with late seizures after requiring an anesthetic between 60 minutes and 24 hours after start of study drug infusion |
Between 60 minutes and 24 hours after start of study drug infusion
|
|
All cause mortality
Tidsramme: From the start of study drug infusion to hospital discharge or day 30
|
All cause mortality to end of study |
From the start of study drug infusion to hospital discharge or day 30
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Jaideep Kapur, MD, PhD, University of Virginia
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Sygdomme i nervesystemet
- Anfald
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Status Epilepticus
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Thiazoler
- Azoler
- Kulbrinter
- Cyclohexanes
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Syrer, acyklisk
- Carboxylsyrer
- Imidazoler
- Amider
- Pyrrolidiner
- Acetamider
- Acetater
- Pyrrolidinoner
- Levetiracetam
- Ketamin
- Levamisol
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HSR231657
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data will be stored in Data Archive for the Brain Initiative (DABI) after trial completion. Once submitted to the data repository, we will work with DABI support to ensure that the de-identified KESETT data is available to the public in the DABI search engine where data requests can be submitted.
IPD-delingstidsramme
The timeline of submission of the public use dataset to the repository will comply with all relevant repository guidelines but in general SIREN will submit data to the repository approximately one year after the primary manuscript of the trial is accepted for publication.
IPD-delingsadgangskriterier
Access to the de-identified dataset will be controlled by the data repository. DABI offers two approaches to data access: public or private. The KESETT team plans to make the de-identified data public which means it will be publicly available for downloading to DABI account holders.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .